[Adverse events of drugs for the treatment of osteoporosis].
Nakamura
Toshitaka
T
Department of Orthopedics, School of Medicine, University of Occupational and Environmental Health, Japan.
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002762:Cholecalciferol / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D007571:Jaw Diseases / Q000473:pathology; D008269:Macular Edema / Q000139:chemically induced; D009336:Necrosis / Q000139:chemically induced; D010024:Osteoporosis / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000139:chemically induced
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D002762:Cholecalciferol; D020849:Raloxifene Hydrochloride